南非正计划收紧药房自行配制药物的规则，包括热门减肥和糖尿病药物奥西美昔（Ozempic）和莫尼珠单抗（Mounjaro），路透社报道。
South Africa is planning to tighten the rules around pharmacies making their own compound versions of medicines, including the popular weight-loss and diabetes treatments Ozempic and Mounjaro, Reuters reports.
此举可能受到诺和诺德和礼来等制药巨头的欢迎，因为它们正试图遏制与其畅销GLP-1药物竞争的药房自制产品。
The move is likely to be welcomed by pharmaceutical giants such as Novo Nordisk and Eli Lilly as they seek to curb the pharmacy-made products competing with their blockbuster GLP-1 drugs.
南非药房委员会首席执行官文森特·特拉拉表示，该组织正与行业监管机构合作，更新药物配制的标准，因为他们担心一些药房实际上已成为“小规模制造商”，提前大量生产药物，而非针对特定患者。
South African Pharmacy Council CEO Vincent Tlala said his organization was working with the industry regulator to update standards governing the compounding of medicines because they are worried that some pharmacies have become, in effect, “small-scale manufacturers,” producing large quantities of treatments in advance, rather than for specific patients.
新指南的讨论预计将于明年三月左右发布，此举紧随六月诺和诺德在法庭上胜诉的局面——当时诺和诺德起诉当地配药药房未经授权复制其药物。南非成人肥胖率在非洲最高，达到30%，因此这些药物需求旺盛，但品牌版药物的高昂成本使得大多数人负担不起。
The discussion on new guidelines, expected to be published around March next year, follows June’s court victory for Novo Nordisk against local compounding pharmacies making unauthorized copies. With the highest adult obesity rate in Africa, at 30%, the drugs are in high demand in South Africa, but the cost of the trademarked version puts them out of reach for most people.
